Revolution Medicines, Inc. balance sheet
At the end of its fiscal year on Dec 31, 2025, Revolution Medicines, Inc. reported total assets of $2.35B and shareholders' equity of $1.63B. That works out to liabilities equal to 31% of assets, a current ratio of 7.14 (current assets ÷ current liabilities).
Balance sheet at each fiscal year end
| Fiscal year ended | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total assets | — | $220.53M | $567.40M | $737.99M | $811.93M | $2.06B | $2.56B | $2.35B |
| Current assets | — | $133.98M | $454.12M | $589.77M | $660.18M | $1.88B | $2.33B | $2.08B |
| Cash & equivalents | $69.59M | $16.66M | $104.27M | $108.50M | $161.41M | $696.15M | $543.06M | $383.75M |
| Total liabilities | — | $67.99M | $92.72M | $135.42M | $126.74M | $235.51M | $293.10M | $723.21M |
| Current liabilities | — | $43.05M | $47.18M | $60.35M | $61.98M | $143.85M | $163.91M | $290.42M |
| Shareholders' equity | −$108.42M | −$152.57M | $474.68M | $602.57M | $685.19M | $1.83B | $2.27B | $1.63B |
| Reported in | 10-K 2021 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 |
Balance-sheet figures are point-in-time values on the last day of each fiscal year. Some companies (for example banks and insurers) do not present current assets and liabilities; those cells show —.
Source: SEC EDGAR XBRL company facts for CIK 1628171 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.